Anti Infectives: World Market, 2nd Edition, Vol II: Antibacterials

 
   Single User - $2,995
   Corporate License - $5,990


Loading...
Published Apr 1, 2007 | 276 Pages | Pub ID: KLI1399449

The market for antibiotics has changed and a knowledge of the current drug resistance situation is critical before operating in this marketplace. The effectiveness of many antibacterials (antibiotics) is being reduced as more and more types of bacteria become resistant to them.

These and other developments are covered in Kalorama's Anti-Infectives, World Markets, Vol. II: Antibacterials providing extensive detail on the anti-bacterial market, including the following critical trends:

  • Drug resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • Addressing Market Trends
  • Antibiotic Use in Agriculture
  • Antibiotic Education
  • Children and Bacterial Resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospital Patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug Resistance
  • Methicillin Resistant Staphylococcus Aureus

The title is part of Kalorama Information's Anti-Infectives series, which represents a total decison and problem-solving support tool for decision makers in the pharmaceutical industry dealing with anti-infectives, or those assisting customers or looking at investments in this area.

Because of antibiotic resitance and other changing dynamics, knowledge of issues and trends is necessary to operate the antibacterials market. In this, the second volume of Kalorama Information's Anti-Infective Markets series, the antibacterial drug market is broken down into seven general categories based on drug class:

  • cephalosporins
  • macrolides
  • penicillins
  • quinolones
  • sulfonamides
  • tetracyclines
  • other misc. antibiotics
There is a significant trend shift occuring in the antibacterials market since Kalorama Information's last edition in 2005. Anti-Infectives Vol. II: Antibacterials covers that shift in detail. For each marketplace segment, Market Size, Growth and Share are provided, and revenue is forecasted to 2011 are provided. Current products are discussed and new pipeline products are assessed. This report also breaks out marketplace data by Infection Type the only publication to do so. In total, over 100 Tables and Figures provide accessible data on this growing market, a depth of coverage unsurpassed by any competitive study.

The following companies are profiled as part of this report:

  • Abbott Laboratories
  • AstraZeneca
  • Bayer Schering Pharma
  • Cubist Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • King Pharmaceuticals
  • Merck & Company, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi-Aventis
  • Wyeth
Executive Summary
  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

Introduction  The World Market for Anti-Infectives Volume 2:           

  • Antibacterial Drugs
  • Introduction to pathogens
    • Classification of Antibacterial Organisms
    • Antimicrobial Spectrum
    • Bacterial Resistance
    • Principles of Anti-infective Therapy
    • Infecting Organism
    • Antibiotic Sensitivity Testing
    • Site of Infection
    • Host Defenses and Organ Function
    • Antibiotic Pharmacokinetics
    • Monitoring Therapy
    • Combination Therapy and Prophylactic Use

  • Demographics and Statistics

Issues and Trends Affecting the Antibacterial Drug Market     

  • introduction
  • Drug Resistance and Interactions
  • Antibiotic Abuse
  • Antibiotic Cycling
  • addressing market trends
  • Antibiotic use in Agriculture
  • Antibiotic Education
  • Children and Bacterial resistance
  • The Elderly and Bacterial Resistance
  • Compromised Individuals and Bacterial Resistance
  • Screening Hospitalized patients
  • Side Effects of Antibiotics
  • Partnerships and Alliances
  • Environment and Drug  Resistance
  • Methicillin-resistant Staphylococcus Aureus (MRSA)

Cephalosporin Antibiotics

  • Overview
  • Description of Products
    • First Generation Cephalosporins
    • Cephalexin (Keflex, Advancis Pharmaceuticals)
    • Cefazolin (Ancef, GlaxoSmithKline; Cefamezin, Astellas)
    • Cefadroxil (Duricef, Bristol-Myers Squibb/Warner Chilcot)
    • Second Generation Cephalosporins
    • Cefuroxime (Ceftin, GlaxoSmithKline)
    • Cefoxitin (Mefoxin, Merck)
    • Third Generation Cephalosporins
    • Cefotaximen (Claforan offered by Sanofi-Aventis)
    • Cefoperazone (Cefobid, Pfizer)
    • Ceftibutin (Cedax, Shionogi)
    • Ceftizoxime (Cefizox, Astellas)
    • Ceftriaxone (Rocephin, Roche)
    • Ceftazidime (Fortaz, GlaxoSmithKline)
    • Cefixime (Suprax, Wyeth/Lupin Pharmaceuticals)
    • Cefpodoxime (Vantin, Pfizer)
    • Fourth Generation Cephalosporins
    • Cefepime (Maxipime, Bristol-Myers Squibb)

  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Macrolide Antibiotics

  • Overview
  • Description of Products
    • Azithromycin (Zithromax, Pfizer; Zmax, Pfizer)
    • Clarithromycin (Biaxin, Abbott Laboratories)
    • Erythromycin (Erythrocin, Abbott Laboratories; EryPed, Abbott Laboratories)
    • Telithromycin (Ketek, Sanofi-Aventis)

  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Penicillin Antibiotics

  • Overview
  • Natural Penicillins
  • Penicillinase-Resistant Penicillins
  • Broad -Spectrum Penicillins
  • Extended-Spectrum Penicillins

Description of Products

  • Natural Penicillins
  • Penicillin G (Bicillin, King Pharmaceuticals; Pfizerpen, Pfizer)
  • Penicillinase-resistant Penicillins
  • Cloxacillin (Cloxapen, GlaxoSmithKline)
  • Oxacillin (Bactocill, GlaxoSmithKline)
  • Broad-spectrum Penicillins
  • Amoxicillin (Augmentin, GlaxoSmithKline; Amoxil,GlaxoSmithKline)
  • Ampicillin (Unasyn, Pfizer)
  • Extended-spectrum Penicillins
  • Carbenicillin (Geocillin, Pfizer)
  • Piperacillin (Pipracil, Wyeth; Zosyn, Wyeth)
  • Ticarcillin (Timentin, GlaxoSmithKline)

  • Generic Drug Impact and Availability
  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

    Quinolone Antibiotics

    • Overview
    • Description of Products
      • Ciprofloxacin (Cipro, Bayer; Proquin XR, Depomed)
      • Gemifloxacin (Factive, LG Chem Ltd. and Oscient Pharmaceuticals)
      • Lomefloxacin (Maxaquin, Unimed)
      • Nalidixic (NegGram, Sanofi-Aventis)
      • Norfloxacin (Noroxin, Merck)
      • Ofloxacin (Floxin, Ortho-McNeil)
      • Moxifloxicin (Avelox, Bayer; Vigamox, Alcon)
      • Levofloxacin (Levaquin, Ortho-McNeil; Tavanic, Sanofi-Aventis; Cravit, Daiichi Sankyo; Quixin, Santen)
      • Gatifloxacin (Zymar, Allergan/Kyorin)
      • Trovafloxacin (Trovan, Pfizer)

    • Generic Drug Impact and Availability
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

    Sulfonamide Antibiotics

    • Overview
    • Description of Products
    • Sulfisoxazole (Gantrisin Pediatric, Roche)
      • Oxytetracycline/Sulfamethizole/Phenazopyridine (Urobiotic, Pfizer)
      • Erythromycin ethylsuccinate and Sulfisoxazole acetyl (Pediazole, Ross)
      • Dapsone (Aczone Gel, QLT USA-Tolmar Inc.)

    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

    Tetracycline Antibiotics

    • Overview
    • Description of Products
    • Generic Drug Impact and Availability
    • Research and Development
    • Market Size and Growth
    • Competitive Analysis

    Other Miscellaneous Antibiotics

    • Overview
    • Description of Products
    • Aminoglycosides
      • Amikacin Sulfate (Amikin, Bristol-Myers Squibb)
      • Kanamycin Sulfate (Kantrex, Bristol-Myers Squibb)
      • Neomycin Sulfate (Neo-fradin, X Gen Pharms)
      • Streptomycin Sulfate (Streptomycin, Pfizer)
      • Lincomycin
      • Clindamycin (Cleocin, Pfizer; Clindesse, KV Pharmaceutical Company; Evoclin, Connetics Corp.; Ziana Gel, Medicis/Dow)
      • Chloramphenicol
      • Chloramphenicol  (Chloromycetin,Pfizer)
      • Glycopeptide
      • Vancomycin (Vancocin,  Viropharma)
      • Monobactams
      • Aztreonam (Azactam, Bristol-Myers Squibb)
      • Carbapenems
      • Imipenem/cilastatin (Primaxin, Merck)
      • Meropenem (Merrem, AstraZeneca)
      • Metronidazole
      • Metronidazole (Flagyl, Pfizer; Pylera, Axcan; Metrogel-Vaginal, 3M Pharmaceuticals; MetroGel, Galderma)
      • Antituberculars
      • Rifampicin (Rifater, Sanofi-Aventis)
      • Capreomycin (Capastat sulfate, Eli Lilly & Co.)
      • Ethionamide (Trecator SC, Wyeth)
      • Aminosalicylic acid granules (Paser Granules, Jacobus Pharmaceutical)
      • Cycloserine (Seromycin, Eli Lilly & Co.)
      • Antileprotics
      • Dapsone (Dapsone, Jacobus)
      • Oxazolidinones
      • Linezolid  (Zyvox, Pfizer)
      • Ketolides
      • Telithromycin (Ketek, Sanofi-Aventis)
      • Lipopeptides
      • Daptomycin (Cubicin, Cubist Pharmaceutical)
      • Glycyclines
      • Tigecycline (Tygacil, Wyeth)
      • Generic Drug Impact and Availability
      • Research and Development
      • Market Size and Growth
      • Competitive Analysis

    Corporate Profiles

    • Introduction
    • Abbott Laboratories
    • AstraZeneca plc
    • Bayer Schering Pharma AG
    • Cubist Pharmaceuticals, Inc
    • Daiichi Sankyo Co., Ltd.
    • GlaxoSmithKline
    • Johnson & Johnson Group
    • King Pharmaceuticals, Inc.
    • Merck & Company, Inc.
    • Pfizer, Inc.
    • Roche
    • Sanofi-Aventis
    • Wyeth

    Company Names and Addresses